Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on February 21, 2013, reporting events occurring on February 18, 2013. The filing discloses the entry into a Material Definitive Agreement with Professional Compounding Centers of America, Inc. ("PCCA").
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the potential compensation structure of the new agreement:
- Upfront Fees: PCCA is entitled to cash fees up to an aggregate of $100,000 upon the Company entering into a commercial agreement with a referred Member/Customer.
- Commissions: PCCA may receive a commission based on net sales generated from acquired intellectual property, though specific rates are not disclosed in this summary.
Material Changes
The primary material change is the execution of a Strategic Alliance Agreement with PCCA. Key terms include:
- Right of First Refusal: PCCA agreed not to introduce its members/customers to third parties for intellectual property licensing without first presenting the opportunity to Imprimis.
- Support Services: PCCA may use reasonable efforts to facilitate introductory meetings and provide technical assistance for potential development projects.
- Term: The agreement is for one year and automatically renews for successive one-year periods unless written notice of non-renewal is given.
Guidance, Risks, and Related Party Matters
Related Party Transaction: August Bassani, a member of Imprimis's Board of Directors, serves as Vice-President of Consulting, R&D and Formulations at PCCA. The filing states that Mr. Bassani did not participate in negotiations and does not have a material pecuniary interest in the transaction.
Risks and Contingencies: The agreement is contingent on Imprimis successfully entering into commercial agreements with referred parties. There is no guarantee that PCCA will present opportunities or that Imprimis will acquire any intellectual property.
Guidance: The filing contains no forward-looking financial guidance or management commentary regarding future earnings or operational outlook beyond the terms of the agreement.
Investor Verification Checklist
- Verify the full text of the Strategic Alliance Agreement (Exhibit 10.1) to understand specific commission rates and technical assistance obligations.
- Confirm the current status of any intellectual property deals resulting from this alliance in subsequent filings.
- Review the Company's cash position to assess its ability to pay the potential $100,000 fee if a deal is closed.
- Monitor for any future disclosures regarding Mr. Bassani's role or potential conflicts of interest.